Improving Outcomes and Mitigating Costs Associated With CAR T-Cell Therapy

Abstract Since the historic approval of tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia in 2017, chimeric antigen receptor (CAR) T-cell therapies have altered the treatment paradigm for hematologic malignancies. Five CAR T-cell products are now approved by the US Food and Drug Administration for a growing number of cancer indications and a global market worth billions is anticipated in the next 5 years.

Read the source article at AJMC
2021-08-18 20:00:00